ipilimumab
UK Researchers Show Cytotoxic T-Cell Level Predicts Melanoma Immunotherapy Response
A Science Immunology paper details how patients with more cytotoxic effector T cells in peripheral blood at baseline respond better to checkpoint inhibitors.
OmniSeq, UPMC Partner on Immunotherapy Trial Matching for Head and Neck Cancer
The Phase II trial will use OmniSeq's RNA-seq assay to determine whether patients should be treated with one of two agents combined with BMS' nivolumab.
Using corrected TMB and other variables allowed Johns Hopkins researchers to more accurately predict response to immune checkpoint blockade in lung cancer.